GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal disease… Read more
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Net Assets
Latest net assets as of September 2025: ₹17.08 Billion INR
Based on the latest financial reports, GlaxoSmithKline Pharmaceuticals Limited (GLAXO) has net assets worth ₹17.08 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹36.65 Billion) and total liabilities (₹19.57 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹17.08 Billion |
| % of Total Assets | 46.59% |
| Annual Growth Rate | 3.81% |
| 5-Year Change | 30.17% |
| 10-Year Change | 15.05% |
| Growth Volatility | 22.72 |
GlaxoSmithKline Pharmaceuticals Limited - Net Assets Trend (2005–2025)
This chart illustrates how GlaxoSmithKline Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GlaxoSmithKline Pharmaceuticals Limited (2005–2025)
The table below shows the annual net assets of GlaxoSmithKline Pharmaceuticals Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹19.51 Billion | +9.77% |
| 2024-03-31 | ₹17.78 Billion | +2.09% |
| 2023-03-31 | ₹17.41 Billion | -34.61% |
| 2022-03-31 | ₹26.63 Billion | +77.64% |
| 2021-03-31 | ₹14.99 Billion | -17.66% |
| 2020-03-31 | ₹18.21 Billion | -14.92% |
| 2019-03-31 | ₹21.40 Billion | +4.01% |
| 2018-03-31 | ₹20.57 Billion | +2.52% |
| 2017-03-31 | ₹20.07 Billion | +18.32% |
| 2016-03-31 | ₹16.96 Billion | -30.60% |
| 2015-03-31 | ₹24.44 Billion | +22.83% |
| 2014-03-31 | ₹19.90 Billion | -0.85% |
| 2013-03-31 | ₹20.07 Billion | +3.67% |
| 2012-03-31 | ₹19.36 Billion | -0.81% |
| 2011-03-31 | ₹19.52 Billion | +9.27% |
| 2010-03-31 | ₹17.86 Billion | +13.36% |
| 2009-03-31 | ₹15.76 Billion | +14.10% |
| 2008-03-31 | ₹13.81 Billion | +14.62% |
| 2007-03-31 | ₹12.05 Billion | +26.40% |
| 2006-03-31 | ₹9.53 Billion | +3.18% |
| 2005-03-31 | ₹9.24 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GlaxoSmithKline Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1058631600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹10.59 Billion | 54.25% |
| Common Stock | ₹1.69 Billion | 8.68% |
| Other Comprehensive Income | ₹7.23 Billion | 37.07% |
| Total Equity | ₹19.51 Billion | 100.00% |
GlaxoSmithKline Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of GlaxoSmithKline Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dottikon Es Holding AG
SW:DESN
|
$1.16 Billion |
|
Fila Holdings Corp
KO:081660
|
$1.16 Billion |
|
Veris Gold Corp
PINK:YNGFF
|
$1.16 Billion |
|
Vantage Towers AG
PINK:VTWRF
|
$1.16 Billion |
|
Jiangsu Wujiang Rural Coml Bk
SHG:603323
|
$1.16 Billion |
|
Infore Environment Technology Group Co Ltd
SHE:000967
|
$1.16 Billion |
|
Verint Systems Inc
NASDAQ:VRNT
|
$1.16 Billion |
|
DEUTZ Aktiengesellschaft
PINK:DEUZF
|
$1.16 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GlaxoSmithKline Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,776,397,000 to 19,513,100,000, a change of 1,736,703,000 (9.8%).
- Net income of 9,275,829,000 contributed positively to equity growth.
- Dividend payments of 7,493,800,000 reduced retained earnings.
- Other comprehensive income decreased equity by 85,254,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹9.28 Billion | +47.54% |
| Dividends Paid | ₹7.49 Billion | -38.4% |
| Other Comprehensive Income | ₹-85.25 Million | -0.44% |
| Other Changes | ₹39.93 Million | +0.2% |
| Total Change | ₹- | 9.77% |
Book Value vs Market Value Analysis
This analysis compares GlaxoSmithKline Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 21.09x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 45.93x to 21.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹52.89 | ₹2429.60 | x |
| 2006-03-31 | ₹55.54 | ₹2429.60 | x |
| 2007-03-31 | ₹71.12 | ₹2429.60 | x |
| 2008-03-31 | ₹81.51 | ₹2429.60 | x |
| 2009-03-31 | ₹93.00 | ₹2429.60 | x |
| 2010-03-31 | ₹105.43 | ₹2429.60 | x |
| 2011-03-31 | ₹115.20 | ₹2429.60 | x |
| 2012-03-31 | ₹114.26 | ₹2429.60 | x |
| 2013-03-31 | ₹118.46 | ₹2429.60 | x |
| 2014-03-31 | ₹117.45 | ₹2429.60 | x |
| 2015-03-31 | ₹144.27 | ₹2429.60 | x |
| 2016-03-31 | ₹100.12 | ₹2429.60 | x |
| 2017-03-31 | ₹118.46 | ₹2429.60 | x |
| 2018-03-31 | ₹121.44 | ₹2429.60 | x |
| 2019-03-31 | ₹126.31 | ₹2429.60 | x |
| 2020-03-31 | ₹107.47 | ₹2429.60 | x |
| 2021-03-31 | ₹87.26 | ₹2429.60 | x |
| 2022-03-31 | ₹157.19 | ₹2429.60 | x |
| 2023-03-31 | ₹102.79 | ₹2429.60 | x |
| 2024-03-31 | ₹104.93 | ₹2429.60 | x |
| 2025-03-31 | ₹115.19 | ₹2429.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GlaxoSmithKline Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 47.54%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.74%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 2.11x
- Recent ROE (47.54%) is above the historical average (30.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 36.56% | 23.95% | 1.00x | 1.53x | ₹2.45 Billion |
| 2006 | 53.21% | 33.40% | 1.00x | 1.59x | ₹4.12 Billion |
| 2007 | 45.74% | 34.83% | 0.88x | 1.49x | ₹4.31 Billion |
| 2008 | 39.65% | 34.05% | 0.79x | 1.47x | ₹4.09 Billion |
| 2009 | 37.52% | 34.91% | 0.73x | 1.47x | ₹4.34 Billion |
| 2010 | 28.43% | 26.62% | 0.76x | 1.40x | ₹3.29 Billion |
| 2011 | 28.72% | 26.06% | 0.77x | 1.44x | ₹3.65 Billion |
| 2012 | 22.14% | 18.02% | 0.78x | 1.58x | ₹2.35 Billion |
| 2013 | 28.00% | 21.17% | 0.86x | 1.54x | ₹3.61 Billion |
| 2014 | 19.15% | 14.45% | 0.84x | 1.57x | ₹1.82 Billion |
| 2015 | 15.59% | 14.45% | 0.82x | 1.32x | ₹1.37 Billion |
| 2016 | 22.18% | 13.25% | 0.93x | 1.80x | ₹2.07 Billion |
| 2017 | 16.78% | 11.58% | 0.97x | 1.50x | ₹1.36 Billion |
| 2018 | 17.05% | 12.21% | 0.73x | 1.92x | ₹1.45 Billion |
| 2019 | 20.81% | 14.24% | 0.80x | 1.83x | ₹2.31 Billion |
| 2020 | 5.12% | 2.89% | 1.03x | 1.72x | ₹-888.56 Million |
| 2021 | 24.23% | 12.24% | 0.94x | 2.11x | ₹2.10 Billion |
| 2022 | 63.64% | 51.70% | 0.71x | 1.74x | ₹14.28 Billion |
| 2023 | 35.07% | 18.78% | 0.98x | 1.91x | ₹4.37 Billion |
| 2024 | 33.19% | 17.08% | 0.97x | 2.00x | ₹4.12 Billion |
| 2025 | 47.54% | 24.74% | 0.91x | 2.11x | ₹7.32 Billion |
Industry Comparison
This section compares GlaxoSmithKline Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $4,671,044,237
- Average return on equity (ROE) among peers: 23.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | ₹17.08 Billion | 36.56% | 1.15x | $1.16 Billion |
| Kopran Limited (KOPRAN) | $1.09 Billion | 9.86% | 1.43x | $31.83 Million |
| Marksans Pharma Limited (MARKSANS) | $9.05 Billion | 26.35% | 0.36x | $405.73 Million |
| NGL Fine-Chem Limited (NGLFINE) | $160.59 Million | 15.04% | 1.05x | $40.08 Million |
| Pfizer Limited (PFIZER) | $9.01 Billion | 33.25% | 0.22x | $823.98 Million |
| Sanofi India Limited (SANOFI) | $17.36 Billion | 17.53% | 0.46x | $361.36 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.08 Billion | 79.43% | 0.66x | $319.07 Million |
| SENORES PHARMACEUTICALS L (SENORES) | $94.96 Million | 7.21% | 0.53x | $159.44 Million |
| SMS Pharmaceuticals Limited (SMSPHARMA) | $2.22 Billion | 9.19% | 1.30x | $97.10 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $982.22 Million | 14.46% | 1.13x | $30.49 Million |